ESPR Q4 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+881.5% YoY

Gross Profit

$8M82.5% margin

Operating Income

-$96M-991.6% margin

Net Income

-$104M-1084.0% margin

EPS (Diluted)

$-3.89

QoQ Revenue Growth

+151.4%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$353M

Total Liabilities

$449M

Stockholders' Equity

-$96M

Cash & Equivalents

$305M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$982,000	+881.5%
Gross Profit	$8M	-$37M	+121.3%
Operating Income	-$96M	-$59M	-62.1%
Net Income	-$104M	-$62M	-68.7%

Revenue Segments

Product

$8M85%

Collaboration Revenue

$1M15%